Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease symbols : Brtx save search
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
BRTX | $1.435 3.24% 3.14% 250K
|
Professional, Scientific, and T...
|
| O: -1.5%
H: 0.0%
C: -2.29%
brtx-100 disease trial
BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease
Published: 2024-02-05 (Crawled : 12:30) - globenewswire.com
BRTX | $1.435 3.24% 3.14% 250K
|
Professional, Scientific, and T...
|
| O: 14.64%
H: 14.33%
C: 7.48%
brtx-100 disease study
BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease
Published: 2023-09-08 (Crawled : 12:30) - globenewswire.com
BRTX | $1.435 3.24% 3.14% 250K
|
Professional, Scientific, and T...
|
| O: 1.59%
H: 0.0%
C: -6.88%
disease health trial phase 2
BioRestorative Therapies Announces Key Milestone of Dosing Completion in Safety Cohort of Phase 2 Trial Targeting Chronic Lumbar Disc Disease
Published: 2023-06-12 (Crawled : 11:00) - globenewswire.com
BRTX | $1.435 3.24% 3.14% 250K
|
Professional, Scientific, and T...
|
| O: 0.57%
H: 1.7%
C: 0.57%
disease trial milestone phase 2
BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease
Published: 2022-12-05 (Crawled : 19:00) - biospace.com/
BRTX | $1.435 3.24% 3.14% 250K
|
Professional, Scientific, and T...
|
| O: 1.19%
H: 18.28%
C: -6.45%
brtx-100 100 disease commercialization program license agreement
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027
Published: 2022-11-15 (Crawled : 14:20) - prnewswire.com
OCEL | $2.75 -98.44% 3.4K
|
Professional, Scientific, and T...
|
| O: 20.68%
H: 22.74%
C: 12.15%
BRTX | $1.435 3.24% 3.14% 250K
|
Professional, Scientific, and T...
|
| O: 0.66%
H: 4.59%
C: -3.61%
VCEL | $43.86 -5.19% -5.47% 430K
|
Health Technology
|
| O: 2.6%
H: 1.14%
C: -1.73%
MDXG | $6.17 -2.53% -2.59% 540K
|
Health Technology
|
| O: 3.69%
H: 3.86%
C: 2.37%
disease expected market
BioRestorative Therapies Announces First Patient Enrolled for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
Published: 2022-06-30 (Crawled : 12:00) - globenewswire.com
BRTX | $1.435 3.24% 3.14% 250K
|
Professional, Scientific, and T...
|
| O: 0.87%
H: 0.58%
C: -14.98%
disease trial therapy phase 2
BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
Published: 2022-06-22 (Crawled : 12:20) - biospace.com/
BRTX | $1.435 3.24% 3.14% 250K
|
Professional, Scientific, and T...
|
| O: 2.76%
H: 0.0%
C: -14.78%
disease contract trial phase 2
BioRestorative Therapies Announces Clinical Site Initiation for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
Published: 2022-06-13 (Crawled : 12:20) - biospace.com/
BRTX | $1.435 3.24% 3.14% 250K
|
Professional, Scientific, and T...
|
| O: -0.88%
H: 0.0%
C: -5.86%
disease trial therapy phase 2
BioRestorative Therapies Hosts Principal Investigator Meeting for its BRTX-100® Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease
Published: 2022-04-29 (Crawled : 14:00) - biospace.com/
BRTX | $1.435 3.24% 3.14% 250K
|
Professional, Scientific, and T...
|
| O: -0.75%
H: 4.62%
C: 1.72%
brtx-100 100 disease trial therapy phase 2
BioRestorative Therapies Announces Selection of 10 Clinical Sites for its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease
Published: 2022-04-18 (Crawled : 13:00) - biospace.com/
BRTX | $1.435 3.24% 3.14% 250K
|
Professional, Scientific, and T...
|
| O: 1.6%
H: 0.0%
C: -4.72%
disease trial therapy phase 2
BioRestorative Therapies Announces it has Initiated its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease – Site Selection Underway
Published: 2022-02-07 (Crawled : 00:00) - biospace.com/
BRTX | $1.435 3.24% 3.14% 250K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 1.76%
C: -3.02%
phase 2 trial disease initiated therapy
BioRestorative Therapies Announces CRO Agreement with PRC Clinical for its BRTX-100 Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease
Published: 2021-12-21 (Crawled : 22:00) - biospace.com/
BRTX | $1.435 3.24% 3.14% 250K
|
Professional, Scientific, and T...
|
| O: -0.43%
H: 2.38%
C: -1.08%
brtx-100 phase 2 trial disease
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.